Similar articles

• Clinical trials report. Vascular effects beyond blood pressure: the CAMELOT study.

  Weber MA. Weber MA. Curr Hypertens Rep. 2005 Aug;7(4):235-7. doi: 10.1007/s11906-005-0017-0. Curr Hypertens Rep. 2005. PMID: 16061038 No abstract available.
• Effect of visit-to-visit blood pressure variability on cardiovascular events in patients with coronary artery disease and well-controlled blood pressure.

  Park S, Yan P, Cerezo C, Jeffers BW. Park S, et al. J Am Soc Hypertens. 2016 Oct;10(10):799-810. doi: 10.1016/j.jash.2016.08.004. Epub 2016 Aug 24. J Am Soc Hypertens. 2016. PMID: 27720066
• CAMELOT tales: trials and tribulations of Sir Lancelot and Lady Guinevere.

  Ventura HO. Ventura HO. Am J Cardiol. 2007 Mar 15;99(6):878. doi: 10.1016/j.amjcard.2006.10.018. Epub 2007 Jan 16. Am J Cardiol. 2007. PMID: 17350390 No abstract available.
• "Successful PTCA:" Camelot or Barnum?

  Baker NH, Brahos GJ, Moore PJ, Sanfelippo PM, McVicker RF, Saltus GL, Miller RL. Baker NH, et al. Ohio Med. 1987 Oct;83(10):721-4. Ohio Med. 1987. PMID: 2960937 Review. No abstract available.
• [Antiatherosclerotic hopes of calcium channel blockers].

  Uetake Y, Shimosawa T. Uetake Y, et al. Clin Calcium. 2005 Oct;15(10):1689-94. Clin Calcium. 2005. PMID: 16199916 Review. Japanese.